Dr. Leslie on Emerging Therapies in MCL

Partner | Cancer Centers | <b>John Theurer Cancer Center</b>

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses emerging therapies in mantle cell lymphoma (MCL).

In recent years, there has been an explosion of therapies in the MCL space, says Leslie.

Currently, emerging agents in the pipeline include BCL-2 inhibitors such as venetoclax (Venclexta), which have the potential to become a standard of care in the future, Leslie says.

Earlier in development, the ROR1 inhibitor cirmtuzumab continues to be studied in combination with ibrutinib (Imbruvica) in MCL and chronic lymphocytic leukemia​, explains Leslie. In MCL, ​the combination has demonstrated an encouraging overall response rate​ and safety profile. 

Additional data on cirmtuzumab in combination with other agents are highly anticipated in the field, Leslie concludes.